SUNSHINE BIOPHARMA’S Adva-27a DESTROYS CANCER CELLS EXPRESSING P-GLYCOPROTEIN, A MARKER PRESENT IN OVER 50% OF ALL CANCER TYPES

For Immediate Release May 25, 2021 Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and commercialization of…

Continue ReadingSUNSHINE BIOPHARMA’S Adva-27a DESTROYS CANCER CELLS EXPRESSING P-GLYCOPROTEIN, A MARKER PRESENT IN OVER 50% OF ALL CANCER TYPES

SUNSHINE BIOPHARMA ELIMINATES $250,000 IN VARIABLE RATE CONVERTIBLE DEBT AND PROVIDES AN UPDATE ON STATUS OF OTCQB UPLISTING

For Immediate Release May 20, 2021 Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of…

Continue ReadingSUNSHINE BIOPHARMA ELIMINATES $250,000 IN VARIABLE RATE CONVERTIBLE DEBT AND PROVIDES AN UPDATE ON STATUS OF OTCQB UPLISTING

SUNSHINE BIOPHARMA UPGRADES COVID-19 PROVISIONAL PATENT APPLICATION TO FULL PCT APPLICATION

For Immediate Release May 4, 2021 Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of…

Continue ReadingSUNSHINE BIOPHARMA UPGRADES COVID-19 PROVISIONAL PATENT APPLICATION TO FULL PCT APPLICATION

SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN EUROPE UNTIL 2033

For Immediate Release March 11, 2021 Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a  pharmaceutical company focused on the research, development and commercialization of oncology…

Continue ReadingSUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN EUROPE UNTIL 2033